Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208741 · ClinicalTrials.gov registry record · Phase 4
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
A Phase 4 study of Social Anxiety Disorder, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT00208741: Completed Phase 4 study of Social Anxiety Disorder, sponsored by Emory University.
NCT00208741 is a Phase 4 study of Social Anxiety Disorder that has completed, run by Emory University. The registered enrollment target is 50 participants, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00208741, a Phase 4 study of Social Anxiety Disorder, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main purpose of this study is to determine how safe and effective Gabitril is for outpatients with Social Anxiety Disorder (SAD).
Conditions Studied
Interventions
- DRUG Gabitril
Study Locations (3)
New York
- Hillside Hospital of the North Shore-Long Island Jewish Health System - Long Island City
- Columbia/New York State Psychiatric Institute - New York
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-11 |
| Phase | Phase 4 |
What the finished NCT00208741 record still lists
NCT00208741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Gabitril is the first listed.
NCT00208741 reports a single indexed study location in New York, Georgia.
Frequently Asked Questions
What is clinical trial NCT00208741 about?
NCT00208741 is a clinical study titled "Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder". The main purpose of this study is to determine how safe and effective Gabitril is for outpatients with Social Anxiety Disorder (SAD).
What is the current status of trial NCT00208741?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2002-06. Estimated completion is 2003-11.
What conditions does trial NCT00208741 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT00208741?
The interventions under investigation include: Gabitril (DRUG).
Who is sponsoring clinical trial NCT00208741?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00208741 being conducted?
This trial has 3 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00208741's enrollment target sits among peer trials
50 26th of 32 higher than 7 of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
COMPLETED · Phase 4
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia